HVAX Technolog. (HVAX)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 30.75% and profit growth of 28.46% show strong recent compounding.
• ROCE of 22.34% at a P/E of 16.13 suggests capital efficiency is not fully expensive.
• PEG of 0.54 indicates the market may be underpricing the growth rate.
• Promoter holding of 66.65% aligns insider interests with minority shareholders.
• Piotroski F-Score of 7/9 provides some reassurance on financial health.

Concerns

• Latest quarter net margin is only about 8.2% (₹5 Cr on ₹61 Cr), leaving a thin buffer.
• No dividend is paid, so total return depends entirely on growth and re-rating.
• Book value, debt-to-equity and ROE are not disclosed, preventing a Graham-style balance-sheet safety check.
• Civil construction is cyclical and competitive; the small ₹196 Cr market cap and wide ₹590–₹887.95 52-week range highlight volatility.

AI Analysis

At first glance, HVAX offers the kind of growth that makes value investors take notice: sales up 30.75% and profits up 28.46%, yet the stock trades at only 16.13 times earnings. A PEG ratio of 0.54 is below 1, implying the market is not paying enough for that growth. ROCE of 22.34% also suggests management is deploying capital well. However, I must temper enthusiasm with my inherent caution. This is civil construction—a cyclical, intensely competitive business. I see no durable moat here, and earnings can vanish when spending slows or tenders turn aggressive. The latest quarter shows net profit of ₹5 Cr on sales of ₹61 Cr, a thin margin of roughly 8.2%; while healthy, it leaves little room for error. With no dividend, the investor is entirely dependent on growth and re-rating. More troubling is the lack of data: book value, debt-to-equity and ROE are unavailable, so I cannot apply Graham's margin-of-safety balance-sheet test. The Piotroski score of 7/9 is reassuring, and promoter holding of 66.65% aligns owner and outsider interests. But a small market cap of ₹196 Cr means price swings can be sharp, as the 52-week range of ₹590–₹887.95 shows. If the company keeps compounding at these rates for several years, ₹804 may prove reasonable. But my rule is to pay a fair price for a wonderful business, not a good price for a cyclical commodity. I would need a lower entry price or clearer evidence of an entrenched niche to build a position. For now, HVAX is an interesting fast grower, not a Buffett-style stalwart.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer